Page last updated: 2024-12-11

ciprostene

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

ciprostene: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6438980
CHEMBL ID2110886
CHEBI ID177626
SCHEMBL ID34269
MeSH IDM0131873

Synonyms (21)

Synonym
unii-kz075bhy4p
ciprostenum [latin]
ciprostenum
pentanoic acid, 5-(hexahydro-5-hydroxy-6-(3-hydroxy-1-octenyl)-3a-methyl-2(1h)-pentalenylidene)-, (3as-(2z,3aalpha,5beta,6alpha(1e,3r*),6aalpha))-
ciprostene [inn]
ciprosteno [spanish]
9beta-methylcarbacyclin
ciprosteno
kz075bhy4p ,
(5z)-5-[(3ar,4r,5r,6as)-5-hydroxy-4-[(e,3s)-3-hydroxyoct-1-enyl]-6a-methyl-1,3,3a,4,5,6-hexahydropentalen-2-ylidene]pentanoic acid
CHEBI:177626
81845-44-5
ciprostene
SCHEMBL34269
pentanoic acid, 5-(hexahydro-5-hydroxy-6-(3-hydroxy-1-octenyl)-3a-methyl-2(1h)-pentalenylidene,(3as-(2z,3a.alpha.,5.beta.,6.alpha.(1e,3r*),6a.alpha.))-
(z)-(3as,5r,6r,6ar)-hexahydro-5-hydroxy-6-((e)-(3s)-3-hydroxy-1-octenyl)-3a-methyl-.delta.(sup 2)(1h),.delta.-pentalenevalerate
CHEMBL2110886
VKPYUUBEDXIQIB-QBPWRKFFSA-N
6,9.alpha.-methylene-9.beta.-methyl-11.alpha.,15s-dihydroxy-prosta-5z,13e-dien-1-oic acid
Q27282512
DTXSID901024660

Research Excerpts

Treatment

ExcerptReferenceRelevance
"Ciprostene treatment elevated cellular cAMP and inhibited U-46619-induced tyrosine phosphorylation on Shc and Shc/GRB2 complex formation."( Activation of thromboxane and prostacyclin receptors elicits opposing effects on vascular smooth muscle cell growth and mitogen-activated protein kinase signaling cascades.
Benjamin, CW; Jones, DA; Linseman, DA, 1995
)
1.01
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
prostanoidThe family of natural prostaglandins and prostaglandin-like compounds including prostacyclins and thromboxanes.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (21)

TimeframeStudies, This Drug (%)All Drugs %
pre-19909 (42.86)18.7374
1990's10 (47.62)18.2507
2000's1 (4.76)29.6817
2010's1 (4.76)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.15

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.15 (24.57)
Research Supply Index3.22 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.15)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (14.29%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other18 (85.71%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]